Cargando…

Syndrome Evaluation System for Simultaneous Detection of Pathogens Causing Acute Encephalitic Syndrome in India, Part-2: Validation Using Well Characterized Clinical Samples

Diagnosis of the aetiological agent in case of acute encephalitic syndrome (AES) continues to pose a challenge in clinical practice as a variety of pathogens are known to cause AES. Here, we report the validation of a Syndrome Evaluation System (SES) developed for simultaneous detection of multiple...

Descripción completa

Detalles Bibliográficos
Autores principales: Govekar, Sunil R., Lakshman, Latha P., Reddy, Vijayalakshmi, Mani, Reeta S., Mahadevan, Anita, Susarla, Shankar K., Desai, Anita, Banda, Ravi Kumar Venkata, Vasanthapuram, Ravi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341057/
https://www.ncbi.nlm.nih.gov/pubmed/30697188
http://dx.doi.org/10.3389/fneur.2018.01193
_version_ 1783388884597473280
author Govekar, Sunil R.
Lakshman, Latha P.
Reddy, Vijayalakshmi
Mani, Reeta S.
Mahadevan, Anita
Susarla, Shankar K.
Desai, Anita
Banda, Ravi Kumar Venkata
Vasanthapuram, Ravi
author_facet Govekar, Sunil R.
Lakshman, Latha P.
Reddy, Vijayalakshmi
Mani, Reeta S.
Mahadevan, Anita
Susarla, Shankar K.
Desai, Anita
Banda, Ravi Kumar Venkata
Vasanthapuram, Ravi
author_sort Govekar, Sunil R.
collection PubMed
description Diagnosis of the aetiological agent in case of acute encephalitic syndrome (AES) continues to pose a challenge in clinical practice as a variety of pathogens are known to cause AES. Here, we report the validation of a Syndrome Evaluation System (SES) developed for simultaneous detection of multiple AES pathogens using a well characterized set of Cerebrospinal fluid (CSF) samples. The validation of the SES was carried out in two phases. In the first phase, the SES was validated using 51 CSF samples obtained from autopsy proven cases and 50 samples obtained from apparently healthy individuals undergoing spinal anesthesia for minor surgeries served as “controls.” The SES detected etilogical agent in 48/51 (94.11 %) samples obtained from autopsy proven AES cases while all the 50 CSF samples obtained from “controls” were negative. In the second phase, the SES was validated using well characterized CSF samples obtained from AES patients fulfilling the WHO case definition of AES (Group I; n = 207) and samples that were collected from patients with non-infectious neurological disorder (Group II; n = 90). All the samples were tested using multiple conventional/serological assays and categorized into various groups. Amongst the AES cases fulfilling WHO case definition, the SES detected AES pathogens in 160/207 (77.29%) cases while conventional serological/molecular assays were able to detect AES pathogens only in 77/207 (37.1%) of cases. Further, in 12/83 CSF samples that were positive by SES and negative by conventional serological/molecular tests, the results were additionally confirmed by sequencing the PCR products to rule out non-specific amplification in the SES. In patients with non-infectious neurological disorders the SES detected latent viruses 12/90 CSF samples. These results indicate that the SES, apart being a rapid, sensitive, specific, and cost-effective method provides the major advantage of simultaneous detection of multiple pathogens using as single specimen of CSF.
format Online
Article
Text
id pubmed-6341057
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63410572019-01-29 Syndrome Evaluation System for Simultaneous Detection of Pathogens Causing Acute Encephalitic Syndrome in India, Part-2: Validation Using Well Characterized Clinical Samples Govekar, Sunil R. Lakshman, Latha P. Reddy, Vijayalakshmi Mani, Reeta S. Mahadevan, Anita Susarla, Shankar K. Desai, Anita Banda, Ravi Kumar Venkata Vasanthapuram, Ravi Front Neurol Neurology Diagnosis of the aetiological agent in case of acute encephalitic syndrome (AES) continues to pose a challenge in clinical practice as a variety of pathogens are known to cause AES. Here, we report the validation of a Syndrome Evaluation System (SES) developed for simultaneous detection of multiple AES pathogens using a well characterized set of Cerebrospinal fluid (CSF) samples. The validation of the SES was carried out in two phases. In the first phase, the SES was validated using 51 CSF samples obtained from autopsy proven cases and 50 samples obtained from apparently healthy individuals undergoing spinal anesthesia for minor surgeries served as “controls.” The SES detected etilogical agent in 48/51 (94.11 %) samples obtained from autopsy proven AES cases while all the 50 CSF samples obtained from “controls” were negative. In the second phase, the SES was validated using well characterized CSF samples obtained from AES patients fulfilling the WHO case definition of AES (Group I; n = 207) and samples that were collected from patients with non-infectious neurological disorder (Group II; n = 90). All the samples were tested using multiple conventional/serological assays and categorized into various groups. Amongst the AES cases fulfilling WHO case definition, the SES detected AES pathogens in 160/207 (77.29%) cases while conventional serological/molecular assays were able to detect AES pathogens only in 77/207 (37.1%) of cases. Further, in 12/83 CSF samples that were positive by SES and negative by conventional serological/molecular tests, the results were additionally confirmed by sequencing the PCR products to rule out non-specific amplification in the SES. In patients with non-infectious neurological disorders the SES detected latent viruses 12/90 CSF samples. These results indicate that the SES, apart being a rapid, sensitive, specific, and cost-effective method provides the major advantage of simultaneous detection of multiple pathogens using as single specimen of CSF. Frontiers Media S.A. 2019-01-15 /pmc/articles/PMC6341057/ /pubmed/30697188 http://dx.doi.org/10.3389/fneur.2018.01193 Text en Copyright © 2019 Govekar, Lakshman, Reddy, Mani, Mahadevan, Susarla, Desai, Banda and Vasanthapuram. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Govekar, Sunil R.
Lakshman, Latha P.
Reddy, Vijayalakshmi
Mani, Reeta S.
Mahadevan, Anita
Susarla, Shankar K.
Desai, Anita
Banda, Ravi Kumar Venkata
Vasanthapuram, Ravi
Syndrome Evaluation System for Simultaneous Detection of Pathogens Causing Acute Encephalitic Syndrome in India, Part-2: Validation Using Well Characterized Clinical Samples
title Syndrome Evaluation System for Simultaneous Detection of Pathogens Causing Acute Encephalitic Syndrome in India, Part-2: Validation Using Well Characterized Clinical Samples
title_full Syndrome Evaluation System for Simultaneous Detection of Pathogens Causing Acute Encephalitic Syndrome in India, Part-2: Validation Using Well Characterized Clinical Samples
title_fullStr Syndrome Evaluation System for Simultaneous Detection of Pathogens Causing Acute Encephalitic Syndrome in India, Part-2: Validation Using Well Characterized Clinical Samples
title_full_unstemmed Syndrome Evaluation System for Simultaneous Detection of Pathogens Causing Acute Encephalitic Syndrome in India, Part-2: Validation Using Well Characterized Clinical Samples
title_short Syndrome Evaluation System for Simultaneous Detection of Pathogens Causing Acute Encephalitic Syndrome in India, Part-2: Validation Using Well Characterized Clinical Samples
title_sort syndrome evaluation system for simultaneous detection of pathogens causing acute encephalitic syndrome in india, part-2: validation using well characterized clinical samples
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6341057/
https://www.ncbi.nlm.nih.gov/pubmed/30697188
http://dx.doi.org/10.3389/fneur.2018.01193
work_keys_str_mv AT govekarsunilr syndromeevaluationsystemforsimultaneousdetectionofpathogenscausingacuteencephaliticsyndromeinindiapart2validationusingwellcharacterizedclinicalsamples
AT lakshmanlathap syndromeevaluationsystemforsimultaneousdetectionofpathogenscausingacuteencephaliticsyndromeinindiapart2validationusingwellcharacterizedclinicalsamples
AT reddyvijayalakshmi syndromeevaluationsystemforsimultaneousdetectionofpathogenscausingacuteencephaliticsyndromeinindiapart2validationusingwellcharacterizedclinicalsamples
AT manireetas syndromeevaluationsystemforsimultaneousdetectionofpathogenscausingacuteencephaliticsyndromeinindiapart2validationusingwellcharacterizedclinicalsamples
AT mahadevananita syndromeevaluationsystemforsimultaneousdetectionofpathogenscausingacuteencephaliticsyndromeinindiapart2validationusingwellcharacterizedclinicalsamples
AT susarlashankark syndromeevaluationsystemforsimultaneousdetectionofpathogenscausingacuteencephaliticsyndromeinindiapart2validationusingwellcharacterizedclinicalsamples
AT desaianita syndromeevaluationsystemforsimultaneousdetectionofpathogenscausingacuteencephaliticsyndromeinindiapart2validationusingwellcharacterizedclinicalsamples
AT bandaravikumarvenkata syndromeevaluationsystemforsimultaneousdetectionofpathogenscausingacuteencephaliticsyndromeinindiapart2validationusingwellcharacterizedclinicalsamples
AT vasanthapuramravi syndromeevaluationsystemforsimultaneousdetectionofpathogenscausingacuteencephaliticsyndromeinindiapart2validationusingwellcharacterizedclinicalsamples